CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
S2101 | SWOG | Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study | Adult CIRB - Late Phase Emphasis | Available to Open |
S1406 | SWOG | Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | Adult CIRB - Early Phase Emphasis | Available to Open |
S1929 | SWOG | Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Adult CIRB - Late Phase Emphasis | Available to Open |
S2210 | SWOG | A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations | Adult CIRB - Late Phase Emphasis | Available to Open |
S1714 | SWOG | A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients | Cancer Prevention and Control CIRB | Available to Open |
S9925 | SWOG | Lung Cancer Specimen Repository Protocol Ancillary | Adult CIRB - Late Phase Emphasis | Completed |
S1314 | SWOG | A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized; Muscle-Invasive Bladder Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
S0421 | SWOG | Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer | Adult CIRB - Late Phase Emphasis | Completed |
S1513 | SWOG | Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer | Adult CIRB - Late Phase Emphasis | Completed |
S2302 | SWOG | Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care (SOC) for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |